From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Interview with Stephanie Giangiuli, PharmD, BCOP: Oral Therapies and Side Effect Management in HR+ HER2- Breast Cancer

Interview with Stephanie Giangiuli, PharmD, BCOP: IV Therapies and Side Effect Management in HR+ HER2- Breast Cancer

Brain Metastases in HR+ HER2- Breast Cancer

Welcome to the new HR+ HER2- Breast Cancer Resource Center! We’re excited to present you with current information, news items, highlights from the literature, and other resources that focus on this disease space and the advanced practitioner’s role in delivering high-quality care to patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Christine McGinn, MSN, APRN, ACNP-BC Oncology Nurse Practitioner Lifespan Cancer Institute	Kate Taucher, PharmD, MHA, BCOP, FASHP, FAPO, FHOPA System Manager, Oncology & Infusion Pharmacy Services PGY2 Oncology Residency Program Director, UCHealth Memorial Hospital

Abemaciclib AE Monitoring

Intravenous Cancer Treatment Education

Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer

HER2 Testing in Breast Cancer - 2023 Guideline Update

Clinical Management of Patients Taking Abemaciclib

Therapeutic Advances in Medical Oncology

Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: A multicenter real-world study

Cureus

Dormancy leading to late recurrence in breast cancer: A case of hormone receptor-positive supraclavicular metastasis 10 years after the initial treatment

Frontiers in Immunology

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions

Clinical Cancer Research

Hormone receptor positive HER2-negative/MammaPrint high-2 breast cancers closely resemble triple negative breast cancers

Cancer Medicine

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer

International Immunopharmacology

Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer

Current Medical Research and Opinion

Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: A systematic review and meta-analysis

ESMO Open

Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States

Oncology Letters

First-line endocrine therapy for hormone receptor positive and HER 2 negative metastatic breast cancer: A Bayesian network meta analysis

Translational Oncology

Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer